Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026

Core Viewpoint - Helix BioPharma Corp. is navigating a challenging capital markets environment while focusing on securing financing to advance its oncology initiatives and aims to list on a U.S. securities exchange [2]. Financial Highlights - The company reported a net loss of $694,000 for the three months ended January 31, 2026, and a loss of $1,702,000 for the six months ended January 31, 2026, compared to a net loss of $1,375,000 and $2,711,000 for the same periods in 2025 [2]. - The loss per common share was $0.01 and $0.05 for the three and six months ended January 31, 2026, respectively, compared to a loss of $0.03 and $0.02 for the same periods in 2025 [2]. - Cash reserves decreased to $31,000 as of January 31, 2026, down from $1,996,000 at the end of the three months ended January 31, 2025, indicating insufficient funds to meet anticipated cash needs for the next twelve months [2]. Financing Activities - The company entered into a subscription agreement with Quantum Global Ventures AG for the purchase of 18,538,889 common shares at $1.80 per share, which was expected to yield gross proceeds of $33,370,000; however, the financing did not close due to Quantum Global Ventures AG declaring bankruptcy [2]. - Following the reporting period, Helix signed a term sheet with Alumni Capital Limited regarding a potential financing transaction, although specific terms are not disclosed [3]. Company Overview - Helix BioPharma is focused on developing innovative solutions for hard-to-treat cancers, with its pipeline led by Tumor Defense Breaker™ L-DOS47, which is designed to enhance the effectiveness of existing cancer therapies [5]. - The company is also advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator, and GEMCEDA™, a first-in-class oral gemcitabine prodrug [5].